Mirococept Biosimilar – Anti-C3 fusion protein – Research Grade from ProteoGenix; catalogue PX-TA2287; research use only.
Know who made it. See the evidence. Buy through one marketplace.
Mirococept Biosimilar is a novel anti-C3 fusion protein that has been developed as a biosimilar to the existing therapeutic antibody, Mirococept. This fusion protein is designed to target the complement protein C3, which plays a crucial role in the inflammatory response and immune system regulation. In this article, we will explore the structure, activity, and potential applications of Mirococept Biosimilar as a research-grade therapeutic agent.
Mirococept Biosimilar is a fusion protein composed of two distinct domains: an anti-C3 antibody fragment and a human C3-derived complement control protein (CCP) domain. The anti-C3 antibody fragment is derived from the variable regions of a monoclonal antibody that specifically binds to the C3b fragment of C3. This fragment is responsible for the opsonization of pathogens and activation of the complement cascade. The CCP domain, on the other hand, acts as a regulator of the complement system by inhibiting the formation of the C3 convertase, a key enzyme in the complement cascade.
The fusion of these two domains creates a unique molecule with both targeting and regulatory capabilities. The anti-C3 antibody fragment allows for specific binding to C3, while the CCP domain helps to prevent excessive complement activation and subsequent tissue damage.
Mirococept Biosimilar works by binding to the C3b fragment of C3, preventing its interaction with other complement proteins and inhibiting the formation of the C3 convertase. This results in the downregulation of the complement cascade and reduces the inflammatory response. Additionally, the binding of Mirococept Biosimilar to C3b can also lead to the clearance of C3b-opsonized pathogens, further contributing to its anti-inflammatory activity.
Moreover, the CCP domain of Mirococept Biosimilar acts as a complement regulator by binding to C3 and preventing its cleavage into C3a and C3b, which are potent inflammatory mediators. This dual mechanism of action makes Mirococept Biosimilar a promising therapeutic agent for various inflammatory and immune-mediated disorders.
Mirococept Biosimilar has shown potential as a research-grade therapeutic agent for a variety of diseases associated with complement dysregulation. Some of the potential applications of this fusion protein include:
1. Autoimmune diseases The complement system has been implicated in the pathogenesis of several autoimmune diseases, including systemic lupus erythematosus, rheumatoid arthritis, and multiple sclerosis. Mirococept Biosimilar has the potential to modulate the complement system and reduce the inflammatory response in these diseases.
2. Inflammatory disorders Inflammation is a key component of many diseases, and the complement system plays a crucial role in this process. By inhibiting the complement cascade, Mirococept Biosimilar has the potential to reduce inflammation and tissue damage in conditions such as sepsis, acute respiratory distress syndrome, and inflammatory bowel disease.
3.
The complement system is an essential component of the innate immune response against pathogens. However, excessive complement activation can lead to tissue damage and contribute to the pathogenesis of infectious diseases. Mirococept Biosimilar has the potential to regulate the complement system and improve the outcome of infections caused by complement-mediated tissue damage.
4.
Complement activation is a major contributor to graft rejection in organ transplantation. By inhibiting the complement cascade, Mirococept Biosimilar has the potential to prevent tissue damage and improve the success rate of organ transplantation.
Mirococept Biosimilar is a promising research-grade therapeutic agent that targets the complement protein C3 and regulates the complement system. Its unique structure and dual mechanism of action make it a potential treatment option for various inflammatory and immune-mediated disorders. Further research and clinical trials are needed to fully explore the
ProteoGenix catalogue number PX-TA2287. For research use only.
Target: C3; Clonality: Monoclonal Antibody; Applications: Block.
Available configurations: 50ug, 100ug, 1mg.
Fully tested in-house by ABMIUM, or supported by an advanced validation report from a partner reviewed by ABMIUM. Highest confidence. Non-conformities fully supported under the ABMIUM Product Promise.
Quality verified. Independent collaborator or expected-performance data available. Product meets ABMIUM quality standards.
Expected to work based on structural and biochemical data. Not yet directly tested by ABMIUM or a collaborator. No non-conformity support for this combination.
Not recommended for this application or species/sample combination. This may indicate either evidence of unsuitability or that the combination has not been tested and therefore cannot currently be recommended.
Evidence status by application and model.
| Target | WB | IHC-P | IHC-Fr | IF/ICC | Flow Cyt | IP | ChIP | ELISA | Block |
|---|---|---|---|---|---|---|---|---|---|
| C3 |
This product is manufactured by ProteoGenix and sold through ABMIUM without relabelling.
ABMIUM supports global orders. Availability, shipping requirements and applicable import arrangements are confirmed before fulfilment where required.
Yes. Send your target, sample, application and experimental conditions through ABMIUM MATCH or technical support.
Unless the listing expressly states otherwise, ABMIUM products are supplied for research use only and are not for diagnostic or therapeutic use.
C3 (complement C3) is the central complement precursor cleaved into C3a and C3b, linking complement activation to inflammatory signalling, opsonization and downstream C5 activation.
Biological function: Complement C3 is activated by C3 convertases across the classical, lectin and alternative pathways. Cleavage generates C3a, an anaphylatoxin involved in inflammatory signalling, and C3b, which covalently labels surfaces for opsonization, supports complement amplification and contributes to C5 convertase formation. Additional processing generates iC3b and other fragments with distinct immune functions.
